The NASA Task Book
Advanced Search     

Project Title:  Reusable Handheld Electrolytes and Lab Technology for Humans (rHEALTH Sensor) Reduce
Fiscal Year: FY 2009 
Division: Human Research 
Research Discipline/Element:
HRP ExMC:Exploration Medical Capabilities
Start Date: 01/09/2009  
End Date: 01/08/2011  
Task Last Updated: 06/18/2009 
Download report in PDF pdf
Principal Investigator/Affiliation:   Chan, Eugene  M.D. / The DNA Medicine Institute 
Address:  727 Massachusetts Avenue 
Boston , MA 02139-3323 
Phone: (617) 233-7656  
Congressional District:
Organization Type: INDUSTRY 
Organization Name: The DNA Medicine Institute 
Joint Agency:  
Project Information: Grant/Contract No. NNX08CB51P 
Responsible Center: NASA JSC 
Grant Monitor: Watkins, Sharmi1a  
Center Contact: 281.483.0395 
Solicitation / Funding Source: SBIR Phase II 
Grant/Contract No.: NNX08CB51P 
Project Type: GROUND 
Flight Program:  
TechPort: No 
No. of Post Docs:  
No. of PhD Candidates:  
No. of Master's Candidates:  
No. of Bachelor's Candidates:  
No. of PhD Degrees:  
No. of Master's Degrees:  
No. of Bachelor's Degrees:  
Human Research Program Elements: (1) ExMC:Exploration Medical Capabilities
Human Research Program Risks: (1) ExMC:Risk of Unacceptable Health and Mission Outcomes Due to Limitations of In-flight Medical Capabilities (IRP Rev E)
(2) Immune:Risk of Adverse Health Event Due to Altered Immune Response (IRP Rev F)
(3) Pharm:Risk of Clinically Relevant Unpredicted Effects of Medication (IRP Rev D)
Human Research Program Gaps: (1) ExMC 4.05:We do not have the capability to measure laboratory analytes in a minimally invasive manner during exploration missions (IRP Rev E)
(2) IM04:Can in-flight hardware to evaluate hematology/infection/immunity be developed? (transferred to HRP infrastructure) (IRP Rev D)
(3) PH04:What diagnostic, therapeutic, and laboratory technologies are necessary to predict and manage medication side effects, interactions, and toxicity during spaceflight? (Incorporated in ExMC 4.05) (IRP Rev D)
Task Description: The goal of the rHEALTH sensor is to provide rapid, low-cost, handheld complete blood count (CBC), cell differential counts, electrolyte measurements, and other lab tests based on a reusable, flow-based microfluidic platform. For Phase II, we will develop an rHEALTH prototype to be delivered to NASA for reusable CBC, cell differential counts, and electrolyte measurements. Each subassembly and individual assay will be tested individually prior to full integration into the system level prototype. The rHEALTH sensor is a compact, portable device that employs cutting-edge fluorescence detection optics, innovative microfluidics, and unique capabilities. Based on its streamlined design, the rHEALTH sensor is able to perform a suite of different assays using a single drop of blood. Furthermore, the entire system allows cost-effective operation because of its nanoliter operating volumes. This is in contrast to existing point-of-care diagnostics devices such as the iSTAT and Piccolo systems which only perform one panel of assays per disposable reagent cartridge. The result is a highly practical, cost-effective, and powerful sensor. The successful completion of the Phase II program is a significant milestone for our rHEALTH sensor. It means that we would have been successful in shrinking hospital-sized clinical laboratory into a portable device.

POTENTIAL NASA COMMERCIAL APPLICATIONS: (1) Real-time health monitoring. The proposed rHEALTH sensor is designed to monitor daily astronaut status so that adverse health events can be managed. (2) Real-time intervention. The ability to measure routine health status allows clinical intervention at appropriate times. (3) Electrolyte measurement on a daily basis for long space flight. (4) CBC measurements on a daily basis. (5) Measurement of cardiac biomarkers for chest pain to rule out myocardial infarction. (6) Measurement of CBC and electrolytes in response to astronaut illness. (7) Monitoring of astronaut renal function to assess volume status. (8) Tracking of bone biomarkers and calcium levels throughout duration of missions to assess intangible bone loss and remodeling.

Research Impact/Earth Benefits: (1) Real-time health monitoring. Development of the rHEALTH allows monitoring of health status in real-time at the bedside or doctor's office. (2) Real-time intervention. Clinical intervention can be accomplished rapidly in acute situations with a handheld monitor. (3) Measurement of daily hematocrit for patients on coumadin or other anti-coagulation to diagnose early blood loss. (4) Detection of acute myocardial damage rapidly and outside the hospital so that life-saving therapy can be administered for heart attack patients. (5) Monitoring resolution of a patient's infection by tracking white blood cell counts throughout a prolonged antibiotic course. (6) Monitoring daily renal function of patients with kidney transplants or those with end-stage renal disease. (7) Measurement of athletes volume status during prolonged training for early diagnosis and dehydration. (8) Daily monitoring of electrolyte status for those individuals taking diuretics. Frequently, diuretics such as furosemide may cause hypokalemia and need to have their daily electrolyte status assessed.

Task Progress & Bibliography Information FY2009 
Task Progress: New project for FY2009. Reporting not required for this SBIR Phase 2 project.

Bibliography Type: Description: (Last Updated: 01/06/2015) 

Show Cumulative Bibliography Listing
 None in FY 2009